Patent · US Active

Antibody-drug conjugate

US10195288B2 · kind B2 · utility

27Cited by

17References

35Claims

0Family size

Assignee

DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

Takeshi Masuda · Tokyo, JP
Hiroyuki Naito · Tokyo, JP
Takashi Nakada · Tokyo, JP
Masao Yoshida · Tokyo, JP
Shinji Ashida · Tokyo, JP
Hideki Miyazaki · Tokyo, JP
Yuji Kasuya · Tokyo, JP
Koji Morita · Tokyo, JP
Yuki Abe · Tokyo, JP
Yusuke Ogitani · Tokyo, JP

Key dates

Filing date	Oct 10, 2013
Grant date	Feb 5, 2019
Priority date	—
Expiry date	Oct 10, 2033

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.